Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
2,525
Views
0
CrossRef citations to date
0
Altmetric
Editorial

When should systemic biologic therapy for psoriasis be discontinued?

Diem-Phuong D. Daoa Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USAView further author information
,
Jessica N. Pixleya Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USACorrespondence[email protected]
View further author information
&
Steven R. Feldmana Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA;b Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA;c Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USAView further author information
Article: 2173516 | Received 20 Jan 2023, Accepted 23 Jan 2023, Published online: 07 Feb 2023

References

  • Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
  • Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269.
  • Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131–1141. Erratum in: JAMA Dermatol. 2022 Dec 1;158(12):1461.
  • Kim HJ, Lebwohl MG. Biologics and psoriasis: the beat goes on. Dermatol Clin. 2019;37(1):29–36.
  • Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969.
  • Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84(1):60–69.
  • Gottlieb AB, Langholff W. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies errata. J Drugs Dermatol. 2020;19(6):573–574.
  • Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7(4):e33486.
  • Masson Regnault M, Shourick J, Jendoubi F, et al. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23(4):433–447.
  • Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9(10):949–958.
  • Valenzuela F, Flores R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics (Sao Paulo). 2021;76:e3015.
  • Puig L, Costanzo A, Muñoz-Elías EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol. 2022;186(5):773–781.
  • Nielsen ML, Petersen TC, Maul JT, et al. Multivariable predictive models to identify the optimal biologic therapy for treatment of patients with psoriasis at the individual level. JAMA Dermatol. 2022;158(10):1149–1156.
  • Galili E, Levy SR, Tzanani I, et al. New-onset guttate psoriasis: a long-term follow-up study. Dermatology. 2022;1–7. DOI:10.1159/000527737

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.